Semaglutide vs. tirzepatide: how to pick a GLP-1 based on your labs

If you've started a GLP-1 conversation with anyone in the last two years, you've heard both drugs come up — usually in the same breath, often as if they're interchangeable.

They're not. Semaglutide and tirzepatide are both injectable, both weekly, and both produce real weight loss in patients with appropriate clinical indications. But they work through different receptor systems, they produce different magnitudes of weight loss in head-to-head trials, and they have meaningfully different side-effect profiles.

Which one fits you depends less on what you've read on TikTok and more on what your bloodwork looks like. Here's the clinician's-eye view.

The mechanism, in one paragraph each.

Semaglutide is a GLP-1 receptor agonist. It mimics the hormone glucagon-like peptide-1, which your gut releases after a meal. GLP-1 signals satiety to your brain, slows gastric emptying so food sits longer, and improves insulin sensitivity. It's the same molecule sold as Ozempic (for diabetes) and Wegovy (for weight loss), and it's the molecule that started the modern GLP-1 era.

Tirzepatide is a dual agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is a second gut hormone that complements GLP-1 — it appears to amplify insulin sensitivity, improve lipid metabolism, and reduce nausea relative to GLP-1 alone. It's the same molecule sold as Mounjaro (for diabetes) and Zepbound (for weight loss).

Short version: semaglutide hits one lever. Tirzepatide hits two.

What the head-to-head data actually says.

The SURMOUNT-5 trial, published in 2025, compared maximum-dose tirzepatide directly against maximum-dose semaglutide over 72 weeks. The headline numbers:

• Tirzepatide patients lost ~20% of body weight on average.
• Semaglutide patients lost ~14% of body weight on average.
• Both groups dramatically outperformed placebo.

That 6-point gap is the largest in any head-to-head obesity trial to date. Tirzepatide is, on the population level, more effective.

But — and this matters — "on average" hides a lot. Some patients are excellent semaglutide responders. Some patients tolerate one drug far better than the other. And the more effective drug isn't always the right drug for you, which brings us to the labs.

What your bloodwork is telling us.

Before prescribing any GLP-1 at DirectCare AI, a US-licensed clinician reviews a full metabolic panel, not just BMI. The data points that actually change the conversation:

• Fasting insulin and HOMA-IR. This tells us how insulin-resistant you are. Patients with severe insulin resistance often respond dramatically to tirzepatide because the GIP component meaningfully improves insulin sensitivity.
• HbA1c and fasting glucose. Prediabetic or diabetic patients have a stronger metabolic argument for tirzepatide; clean glucose metabolism makes the comparison narrower.
• Lipid panel — particularly triglycerides. Both drugs improve triglycerides, but tirzepatide has the larger published effect.
• TSH and free T3/T4. If your thyroid is under-functioning, no GLP-1 is going to do what you want until that's corrected first.
• Liver enzymes (ALT, AST). Elevated liver enzymes — often from NAFLD/MASLD — are common in the population using GLP-1s, and both drugs improve them, but it changes how we monitor you.
• Sex hormones. Low testosterone in men or undiagnosed PCOS in women can both look like "stubborn weight" and need to be in the protocol conversation.

Side effects: what's the same, what's different.

Both drugs share the GLP-1 side-effect profile: nausea, fullness, occasional reflux, constipation, fatigue in the first 2–4 weeks of each dose escalation. For most patients these are mild and resolve. For a small minority they're protocol-stopping.

Where they diverge:

• Tirzepatide tends to produce less nausea, milligram-for-milligram. The GIP component appears to soften the gut symptoms.
• Tirzepatide is more potent at appetite suppression at higher doses, which is a double-edged sword: better weight-loss outcomes, but a small number of patients eat too little and feel weak.
• Semaglutide has a longer real-world track record (years more on the market in its modern form), which matters to some patients who weigh long-term familiarity heavily.

Both drugs carry a boxed warning regarding thyroid C-cell tumors in animal studies — the human relevance is debated but it means a personal or family history of medullary thyroid carcinoma or MEN2 is a hard contraindication for both.

Dosing and titration.

For weight loss, neither drug starts at its therapeutic dose. You titrate up over months:

• Semaglutide: typically starts at 0.25 mg/week, increases roughly every 4 weeks through 0.5, 1.0, 1.7, and 2.4 mg. The 2.4 mg dose is where the major weight-loss effect lives.
• Tirzepatide: typically starts at 2.5 mg/week, increases every 4 weeks through 5, 7.5, 10, 12.5, and 15 mg. The 10–15 mg range is where the most dramatic effects appear.

Good clinical practice is to never escalate faster than the gut tolerates. The patient who pushes through dose escalations too quickly tends to be the patient who quits the protocol entirely from side effects in month 3.

Cost, access, and compounded options.

Branded versions of both drugs are expensive (often $1,000–1,400/month out of pocket without insurance, less with coverage). Both have credible compounded equivalents — same active ingredient, prepared by US-licensed compounding pharmacies under clinician oversight — at a fraction of the cost.

At DirectCare AI we offer both compounded semaglutide and compounded tirzepatide protocols, with the choice driven by your bloodwork and your clinician's recommendation rather than by which drug you Googled first.

The honest summary.

Tirzepatide is, on average, the more powerful drug. But "more powerful" doesn't equal "better for you." The right protocol is the one your clinician picks after looking at your bloodwork — not the one that trended on social media this month.

If you're considering a GLP-1, the conversation worth having is: what do my labs actually say, and which mechanism matches them? That's a much more useful starting point than the brand name.

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved as finished products; their active ingredients are individually FDA-approved. Always consult a US-licensed clinician before starting or changing any therapy.